1. Home
  2. MNTSW vs TGTX Comparison

MNTSW vs TGTX Comparison

Compare MNTSW & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNTSW
  • TGTX
  • Stock Information
  • Founded
  • MNTSW N/A
  • TGTX 1993
  • Country
  • MNTSW United States
  • TGTX United States
  • Employees
  • MNTSW 123
  • TGTX N/A
  • Industry
  • MNTSW Military/Government/Technical
  • TGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MNTSW Industrials
  • TGTX Health Care
  • Exchange
  • MNTSW Nasdaq
  • TGTX Nasdaq
  • Market Cap
  • MNTSW N/A
  • TGTX 5.5B
  • IPO Year
  • MNTSW 2019
  • TGTX 1995
  • Fundamental
  • Price
  • MNTSW $0.04
  • TGTX $34.89
  • Analyst Decision
  • MNTSW
  • TGTX Strong Buy
  • Analyst Count
  • MNTSW 0
  • TGTX 6
  • Target Price
  • MNTSW N/A
  • TGTX $47.50
  • AVG Volume (30 Days)
  • MNTSW N/A
  • TGTX 1.7M
  • Earning Date
  • MNTSW N/A
  • TGTX 11-03-2025
  • Dividend Yield
  • MNTSW N/A
  • TGTX N/A
  • EPS Growth
  • MNTSW N/A
  • TGTX N/A
  • EPS
  • MNTSW N/A
  • TGTX 0.36
  • Revenue
  • MNTSW N/A
  • TGTX $454,069,000.00
  • Revenue This Year
  • MNTSW N/A
  • TGTX $82.22
  • Revenue Next Year
  • MNTSW N/A
  • TGTX $47.76
  • P/E Ratio
  • MNTSW N/A
  • TGTX $96.10
  • Revenue Growth
  • MNTSW N/A
  • TGTX 30.96
  • 52 Week Low
  • MNTSW N/A
  • TGTX $22.61
  • 52 Week High
  • MNTSW N/A
  • TGTX $46.48
  • Technical
  • Relative Strength Index (RSI)
  • MNTSW 58.51
  • TGTX 56.98
  • Support Level
  • MNTSW $0.04
  • TGTX $33.10
  • Resistance Level
  • MNTSW $0.07
  • TGTX $35.64
  • Average True Range (ATR)
  • MNTSW 0.01
  • TGTX 1.21
  • MACD
  • MNTSW 0.00
  • TGTX -0.14
  • Stochastic Oscillator
  • MNTSW 39.82
  • TGTX 41.03

About MNTSW Momentus Inc. Warrant

Momentus Inc offers in-space infrastructure services by building transfer and service vehicles that carry satellites and hosted payloads between orbits in space. It is a provider of three critical functions, in the new space economy: Space Transportation, Satellite as a Service, and In-Orbit Servicing.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: